Showing 1651-1660 of 1732 results for "".
- FDA Grants 510(k) Clearance to Thin-Film SEEG-Guided Radiofrequency Ablation System for Neurosurgeryhttps://practicalneurology.com/news/fda-grants-510k-clearance-to-thin-film-seeg-guided-radiofrequency-ablation-system-for-neurosurgery/2470363/The Food and Drug Administration (FDA) has granted 510(k) clearance to the OneRF Ablation System (NeuroOne, Eden Prairie, MN), according to an announcement from NeuroOne. The OneRF Ablation System produces radiofrequencies that generate heat to ablate nervous tissue for use in neurosurgery, with
- Subcutaneous Ocrevus Similar to IV Treatment for Patients with PPMS or RMShttps://practicalneurology.com/news/subcutaneous-ocrevus-similar-to-iv-treatment-for-patients-with-ppms-or-rms/2470252/Subcutaneous injection of Ocrevus (ocrelizumab; Genentech, South San Francisco, CA) was comparable to the intravenous (IV) infusion formulation of Ocrevus in treating patients with primary progressive multiple sclerosis (PP
- Foslevodopa/Foscarbidopa Treatment for Advanced Parkinson Disease Associated with Significant Quality of Life Improvements According to Interim Analysis of Clinical Trial Datahttps://practicalneurology.com/news/foslevodopafoscarbidopa-treatment-for-advanced-parkinson-disease-associated-with-significant-quality-of-life-improvements-according-to-interim-analysis-of-clinical-trial-data/2470237/Patients with advanced Parkinson disease (aPD) treated with foslevodopa/foscarbidopa (ABBV-951, AbbVie; North Chicago, IL), a soluble formulation of levodopa/carbidopa prodrugs delivered as a 24-hour/day continuous subcutan
- Approval and Orphan Drug Exclusivity Granted by FDA For Sodium Oxybate to Treat Cataplexyhttps://practicalneurology.com/news/approval-and-orphan-drug-exclusivity-granted-by-fda-for-sodium-oxybate-to-treat-cataplexy/2470174/The Food and Drug Administration (FDA) has granted approval for an extended-release formulation of the central nervous system depressant sodium oxybate (Lumryz; Avadel Pharmaceuticals, Dublin, Ireland) to treat cataplexy or
- Antidepressants Safe in Those Taking Ozanimod for Relapsing MShttps://practicalneurology.com/news/antidepressants-safe-in-those-taking-ozanimod-for-relapsing-ms/2470123/Data presented at the Americas Committee for Treatment & Research in Multiple Sclerosis (ACTRIMS) Forum 2023 suggest that concurrent administration of ozanimod (Zeposia; Bristol Myers Squibb, New York, NY) with selectiv
- Phase 3 Trial of New Drug To Treat Progressive MS Approved by FDAhttps://practicalneurology.com/news/phase-3-trial-of-new-drug-to-treat-progressive-ms-cleared-by-fda/2470089/The Food and Drug Administration (FDA) approved a phase 3 clinical trial (NCT05441488) for masitinib (AB Science; Paris, France) as a potential treatment for progressive forms of multiple sclerosi
- FDA Approves Monoclonal Antibody for Treating Relapsing MShttps://practicalneurology.com/news/fda-approves-monoclonal-antibody-for-treating-relapsing-ms/2470088/The Food and Drug Administration (FDA) approved ublituximab (Briumvi; TG Therapeutics, New York, NY) for treating relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
- Liquid Suspension of Zonisamide Available for Oral Administration to Treat Partial Seizures in Adultshttps://practicalneurology.com/news/liquid-suspension-of-zonisamide-available-for-oral-administration-to-treat-partial-seizures-in-adults/2470047/Zonisamide (Zonisade; Azurity Pharmaceuticals, Woburn, MA), an antiseizure medication for treatment of partial seizures, will become available as a liquid suspension (100 mg/5 mL) in retail pharmacies on October 17, 2022. The oral liquid formulation of zonisamide is FDA- approved and is the only
- Transdermal Donepezil Now Available in UShttps://practicalneurology.com/news/transdermal-donepezil-now-available-in-us/2470041/A once-weekly delivery system for donepezil (Adlarity; Corium, Boston, MA) is now available for prescription in the US. Transdermal donepezil was approved for for treating patients with mild, moderate, or severe dementia due to Alzheimer disease in March 2022. This formulation of
- Virtual Reality Experience May Aid Parkinson Disease Diagnosis and Gait Evaluationhttps://practicalneurology.com/news/virtual-reality-experience-may-aid-parkinson-disease-diagnosis-and-gait-evaluation/2469992/Researchers at Cleveland Clinic have developed a virtual reality (VR) experience with the intention of using the platform to identify early-stage Parkinson disease (PD) and better treat freezing of gait in individuals with PD. The VR platform (Infinadeck; Infinadeck, Rocklin, CA)